Psychopharmacology

, 200:413 | Cite as

Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice

  • Maxine Norcross
  • Mathur Poonam
  • Abigail J. Enoch
  • Rose-Marie Karlsson
  • Jonathan L. Brigman
  • Heather A. Cameron
  • Judith Harvey-White
  • Andrew Holmes
Original Investigation

Abstract

Rationale

5-Hydroxytryptamine (5-HT, serotonin) plays a major role in brain ontogeny. Disruption of 5-HT during early postnatal development produces lasting changes in rodent ‘emotion-related’ behaviors. Adverse effects of treatment with serotonin reuptake inhibitor (SRI) antidepressants have been reported in human adolescents. However, the long-term effects of chronic SRI treatment during adolescence in rodents remain unclear.

Objectives

The objectives of the study are to assess the effects of fluoxetine treatment throughout the adolescent period in measures of fear-, anxiety- and stress-related endpoints in drug-free adults and to examine these effects in two genetic strains of mice differing in baseline stress- and anxiety-related behaviors and sensitivity to SRIs.

Materials and methods

C57BL/6J and BALB/cJ mice received one of two fluoxetine doses for 4 weeks during adolescence (3–7 weeks old). A separate group of C57BL/6J and BALB/cJ mice received fluoxetine for 4 weeks during adulthood (8–12 weeks old). After a 3-week washout period, mice were tested for anxiety-like behaviors (novel open field, elevated plus-maze), fear conditioning and extinction, and stress-related responses to forced swim, as well as serotonin brain levels.

Results

Adolescent fluoxetine treatment did not increase adult measures of anxiety-, fear- or stress-related behaviors, or brain serotonin levels. The same duration of treatment in adulthood also had no effects on these measures when tested after a 3-week washout period.

Conclusions

In clear contrast with emotion-related abnormalities caused by preadolescent fluoxetine treatment or genetic inactivation of fluoxetine’s pharmacological target, the 5-HT transporter, fluoxetine treatment throughout mouse adolescence did not produce detectable, lasting abnormalities in either “high” or “low anxiety” inbred mouse strains.

Keywords

Fluoxetine SSRI Antidepressant Mouse Anxiety Fear Depression Stress Development Serotonin 

References

  1. Alexandre C, Popa D, Fabre V, Bouali S, Venault P, Lesch KP, Hamon M, Adrien J (2006) Early life blockade of 5-hydroxytryptamine 1A receptors normalizes sleep and depression-like behavior in adult knock-out mice lacking the serotonin transporter. J Neurosci 26:5554–5564PubMedCrossRefGoogle Scholar
  2. Andersen SL, Dumont NL, Teicher MH (2002) Differences in behavior and monoamine laterality following neonatal clomipramine treatment. Dev Psychobiol 41:50–57PubMedCrossRefGoogle Scholar
  3. Anisman H, Hayley S, Kelly O, Borowski T, Merali Z (2001) Psychogenic, neurogenic, and systemic stressor effects on plasma corticosterone and behavior: mouse strain-dependent outcomes. Behav Neurosci 115:443–454PubMedCrossRefGoogle Scholar
  4. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306:879–881PubMedCrossRefGoogle Scholar
  5. Ansorge MS, Hen R, Gingrich JA (2007) Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol 7:8–17PubMedCrossRefGoogle Scholar
  6. Ansorge MS, Morelli E, Gingrich JA (2008) Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 28:199–207PubMedCrossRefGoogle Scholar
  7. Belzung C, Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125:141–149PubMedCrossRefGoogle Scholar
  8. Bhansali P, Dunning J, Singer SE, David L, Schmauss C (2007) Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric G-protein G q. J Neurosci 27:1467–1473PubMedCrossRefGoogle Scholar
  9. Bolivar VJ, Pooler O, Flaherty L (2001) Inbred strain variation in contextual and cued fear conditioning behavior. Mamm Genome 12:651–656PubMedCrossRefGoogle Scholar
  10. Bothe GW, Bolivar VJ, Vedder MJ, Geistfeld JG (2005) Behavioral differences among fourteen inbred mouse strains commonly used as disease models. Comp Med 55:326–334PubMedGoogle Scholar
  11. Boyce-Rustay JM, Holmes A (2006) Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31:2405–2414PubMedCrossRefGoogle Scholar
  12. Boyce-Rustay JM, Cameron HA, Holmes A (2007) Chronic swim stress alters sensitivity to acute behavioral effects of ethanol in mice. Physiol Behav 91:77–86PubMedCrossRefGoogle Scholar
  13. Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE (2004) The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 55:1171–1178PubMedCrossRefGoogle Scholar
  14. Cryan JF, Holmes A (2005) The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4:775–790PubMedCrossRefGoogle Scholar
  15. Dohler KD, Wuttke W (1975) Changes with age in levels of serum gonadotropins, prolactin and gonadal steroids in prepubertal male and female rats. Endocrinology 97:898–907PubMedCrossRefGoogle Scholar
  16. Dulawa SC, Holick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29:1321–1330PubMedCrossRefGoogle Scholar
  17. Feng P, Ma Y, Vogel GW (2001) The critical window of brain development from susceptive to insusceptive. Effects of clomipramine neonatal treatment on sexual behavior. Brain Res Dev Brain Res 129:107–110PubMedCrossRefGoogle Scholar
  18. Gaspar P, Cases O, Maroteaux L (2003) The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4:1002–1012PubMedCrossRefGoogle Scholar
  19. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ (2007) Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356–1363PubMedCrossRefGoogle Scholar
  20. Gross C, Hen R (2004) The developmental origins of anxiety. Nat Rev Neurosci 5:545–552PubMedCrossRefGoogle Scholar
  21. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R (2002) Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416:396–400PubMedCrossRefGoogle Scholar
  22. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332–339PubMedCrossRefGoogle Scholar
  23. Handley SL, Mithani S (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of ‘fear’-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol 327:1–5PubMedCrossRefGoogle Scholar
  24. Hansen HH, Sanchez C, Meier E (1997) Neonatal administration of the selective serotonin reuptake inhibitor Lu 10-134-C increases forced swimming-induced immobility in adult rats: a putative animal model of depression? J Pharmacol Exp Ther 283:1333–1341PubMedGoogle Scholar
  25. Hariri AR, Holmes A (2006) Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci 10:182–191PubMedCrossRefGoogle Scholar
  26. Hefner K, Holmes A (2007a) An investigation of the behavioral actions of ethanol across adolescence in mice. Psychopharmacology (Berl) 191:311–22CrossRefGoogle Scholar
  27. Hefner K, Holmes A (2007b) Ontogeny of fear-, anxiety- and depression-related behavior across adolescence in C57BL/6J mice. Behav Brain Res 176:210–215PubMedCrossRefGoogle Scholar
  28. Hilakivi LA, Hilakivi I (1987) Increased adult behavioral ‘despair’ in rats neonatally exposed to desipramine or zimeldine: an animal model of depression? Pharmacol Biochem Behav 28:367–369PubMedCrossRefGoogle Scholar
  29. Hohmann CF, Hamon R, Batshaw ML, Coyle JT (1988) Transient postnatal elevation of serotonin levels in mouse neocortex. Brain Res 471:163–166PubMedGoogle Scholar
  30. Holick KA, Lee DC, Hen R, Dulawa SC (2007) Behavioral Effects of Chronic Fluoxetine in BALB/cJ Mice Do Not Require Adult Hippocampal Neurogenesis or the Serotonin 1A Receptor. Neuropsychopharmacology 33:406–417PubMedCrossRefGoogle Scholar
  31. Holmes A (2008) Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev doi:10.1016/j.neurobiorev.2008.03.006
  32. Holmes A, Rodgers RJ (2003) Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine. Eur J Pharmacol 459:221–230PubMedCrossRefGoogle Scholar
  33. Holmes A, Parmigiani S, Ferrari PF, Palanza P, Rodgers RJ (2000) Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Physiol Behav 71:509–516PubMedCrossRefGoogle Scholar
  34. Holmes A, le Guisquet AM, Vogel E, Millstein RA, Leman S, Belzung C (2005) Early life genetic, epigenetic and environmental factors shaping emotionality in rodents. Neurosci Biobehav Rev 29:1335–1346PubMedCrossRefGoogle Scholar
  35. LaRoche RB, Morgan RE (2007) Adolescent fluoxetine exposure produces enduring, sex-specific alterations of visual discrimination and attention in rats. Neurotoxicol Teratol 29:96–107PubMedCrossRefGoogle Scholar
  36. Lidov HG, Molliver ME (1982a) An immunohistochemical study of serotonin neuron development in the rat: ascending pathways and terminal fields. Brain Res Bull 8:389–430PubMedCrossRefGoogle Scholar
  37. Lidov HG, Molliver ME (1982b) Immunohistochemical study of the development of serotonergic neurons in the rat CNS. Brain Res Bull 9:559–604PubMedCrossRefGoogle Scholar
  38. Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155:315–322CrossRefGoogle Scholar
  39. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, Paul IA (2006a) Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 31:47–57PubMedGoogle Scholar
  40. Maciag D, Williams L, Coppinger D, Paul IA (2006b) Neonatal citalopram exposure produces lasting changes in behavior which are reversed by adult imipramine treatment. Eur J Pharmacol 532:265–269PubMedCrossRefGoogle Scholar
  41. Millstein RA, Holmes A (2007) Effects of repeated maternal separation on anxiety- and depression-related phenotypes in different mouse strains. Neurosci Biobehav Rev 31:3–17PubMedCrossRefGoogle Scholar
  42. Mitchell JB, Iny LJ, Meaney MJ (1990) The role of serotonin in the development and environmental regulation of type II corticosteroid receptor binding in rat hippocampus. Brain Res Dev Brain Res 55:231–235PubMedCrossRefGoogle Scholar
  43. Porsolt RD, Bertin A, Jalfre M (1978) “Behavioural despair” in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51:291–294PubMedCrossRefGoogle Scholar
  44. Prathiba J, Kumar KB, Karanth KS (1995) Effects of neonatal clomipramine on cholinergic receptor sensitivity and passive avoidance behavior in adult rats. J Neural Transm Gen Sect 100:93–99PubMedCrossRefGoogle Scholar
  45. Schmidt HD, Duman RS (2007) The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18:391–418PubMedCrossRefGoogle Scholar
  46. Spear LP, Brake SC (1983) Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 16:83–109PubMedCrossRefGoogle Scholar
  47. Stenfors C, Ross SB (2002) Evidence for involvement of 5-hydroxytryptamine(1B) autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine. Life Sci 71:2867–2880PubMedCrossRefGoogle Scholar
  48. Usala T, Clavenna A, Zuddas A, Bonati M (2008) Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol 18:62–73PubMedCrossRefGoogle Scholar
  49. Velazquez-Moctezuma J, Diaz Ruiz O (1992) Neonatal treatment with clomipramine increased immobility in the forced swim test: an attribute of animal models of depression. Pharmacol Biochem Behav 42:737–739PubMedCrossRefGoogle Scholar
  50. Wellman CL, Izquierdo A, Garret JE, Martin KP, Carroll J, Millstein R, Lesch KP, Murphy DL, Holmes A (2007) Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J Neurosci 27:684–691PubMedCrossRefGoogle Scholar
  51. Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM (1996) Serotonin as a developmental signal. Behav Brain Res 73:19–29PubMedCrossRefGoogle Scholar
  52. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341–1345PubMedCrossRefGoogle Scholar
  53. Wiedholz LM, Owens WA, Horton RE, Feyder M, Karlsson RM, Hefner K, Sprengel R, Celikel T, Daws LC, Holmes A (2008) Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors. Mol Psychiatry 13:631–640PubMedCrossRefGoogle Scholar
  54. Willott JF, Turner JG, Carlson S, Ding D, Seegers Bross L, Falls WA (1998) The BALB/c mouse as an animal model for progressive sensorineural hearing loss. Hear Res 115:162–174PubMedCrossRefGoogle Scholar
  55. Yang RJ, Mozhui K, Karlsson RM, Cameron HA, Williams RW, Holmes A (2008) Variation in mouse basolateral amygdala volume is associated with differences in stress reactivity and fear learning. Neuropsychopharmacology doi:10.1038/sj.npp.1301665
  56. Yoo HS, Bunnell BN, Crabbe JB, Kalish LR, Dishman RK (2000) Failure of neonatal clomipramine treatment to alter forced swim immobility: chronic treadmill or activity-wheel running and imipramine. Physiol Behav 70:407–411PubMedCrossRefGoogle Scholar
  57. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG (2004) Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 305:217PubMedCrossRefGoogle Scholar

Copyright information

© U.S. Government 2008

Authors and Affiliations

  • Maxine Norcross
    • 1
  • Mathur Poonam
    • 1
  • Abigail J. Enoch
    • 1
  • Rose-Marie Karlsson
    • 2
    • 3
  • Jonathan L. Brigman
    • 1
  • Heather A. Cameron
    • 4
  • Judith Harvey-White
    • 5
  • Andrew Holmes
    • 1
  1. 1.Section on Behavioral Science and Genetics, Laboratory for Integrative NeuroscienceNational Institute on Alcohol Abuse and Alcoholism, National Institutes of HealthRockvilleUSA
  2. 2.Laboratory of Translational and Clinical StudiesInstitute on Alcohol Abuse and Alcoholism, NIHBethesdaUSA
  3. 3.Department of Clinical NeuroscienceKarolinska InstituteStockholmSweden
  4. 4.Unit on Neuroplasticity, Mood and Anxiety Disorders ProgramNational Institute of Mental Health, NIHBethesdaUSA
  5. 5.Laboratory for Physiologic StudiesNational Institute on Alcohol Abuse and Alcoholism, NIHRockvilleUSA

Personalised recommendations